Thursday, July 16, 2020 7:23:10 AM
7:04 am ET July 16, 2020 (Benzinga) Print
Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study
ACI-35.030 is a clinical stage vaccine generated with the proprietary SupraAntigen™ platform addressing proteinopathies across neurodegenerative diseases
LAUSANNE, Switzerland, July 16, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the initiation of the second highest dosing group in the Company's Phase 1b/2a clinical trial evaluating ACI-35.030 for the treatment of Alzheimer's disease (AD). The decision to advance to the higher dosing group follows encouraging interim safety, tolerability and immunogenicity results from the initial dosing group.
Immunization with anti-Tau vaccines has become an important strategy for the treatment of AD and other neurodegenerative diseases characterized by Tau pathology. ACI-35.030, which is being developed in collaboration with Janssen Pharmaceuticals, Inc., is the first AD vaccine candidate designed to generate a specific antibody response against pathologic phospho-Tau (pTau) proteins in the brain. Anti-pTau antibodies generated by ACI-35.030 have the potential to reduce the spread and seeding of Tau pathology throughout the brain.
New York Yankees and Duke Basketball
Recent ACIU News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:30:11 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2024 12:53:22 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/03/2024 09:19:30 PM
- AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases • GlobeNewswire Inc. • 01/03/2024 01:10:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/28/2023 09:22:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/19/2023 01:53:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/15/2023 10:27:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/15/2023 09:31:21 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/15/2023 12:27:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/11/2023 09:18:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/06/2023 09:37:10 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/01/2023 12:13:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/03/2023 11:30:08 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2023 08:17:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2023 08:23:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/17/2023 08:15:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/09/2023 08:16:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/08/2023 08:20:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/04/2023 11:30:36 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/26/2023 11:17:17 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/24/2023 08:22:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/21/2023 08:08:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/18/2023 08:09:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/13/2023 08:23:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/12/2023 08:07:33 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM